|Bid||82.92 x 1000|
|Ask||82.99 x 2200|
|Day's Range||82.65 - 83.15|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.11|
|Dividend & Yield||2.72 (3.28%)|
|1y Target Est||N/A|
The first new malaria drug to emerge for 20 years is beginning clinical trials in nine countries across Africa and Asia. KAF156 could be "a game changer", its developers say, at a time when the ...
Novartis AG began testing a new anti-malaria pill in Africa, advancing development of an alternative to its most effective treatment that billionaire philanthropist Bill Gates said risked losing potency....
The therapy, Besponsa, treats a rapidly progressing version of the disease.